NASDAQ:CHEK Check-Cap (CHEK) Stock Price, News & Analysis $0.78 +0.00 (+0.50%) Closing price 03:59 PM EasternExtended Trading$0.79 +0.01 (+0.64%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Check-Cap Stock (NASDAQ:CHEK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Check-Cap alerts:Sign Up Key Stats Today's Range$0.77▼$0.7950-Day Range$0.73▼$1.0352-Week Range$0.56▼$3.04Volume20,722 shsAverage Volume380,265 shsMarket Capitalization$4.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Check-Cap Ltd. (NASDAQ: CHEK) is a medical technology company focused on transforming colorectal cancer screening through its novel C-Scan system. Headquartered in Israel with offices in the United States, Check-Cap develops and commercializes an ingestible, low-dose X-ray capsule designed to generate high-resolution, three-dimensional images of the colon. The company’s mission is to offer a more patient-friendly alternative to conventional colonoscopy, reducing discomfort and preparation requirements while maintaining diagnostic accuracy. The core offering of Check-Cap is the C-Scan platform, which combines a swallowable capsule with an external detector and proprietary software. Once ingested, the capsule travels naturally through the gastrointestinal tract, emitting ultra-low-dose X-rays that are captured by a sensor belt worn by the patient. The data are then reconstructed into detailed colon images for physician review. By eliminating sedation and minimizing the need for extensive bowel preparation, this technology aims to increase screening compliance among individuals at average risk of colorectal cancer. Founded in 2004, Check-Cap has completed multiple clinical studies in Israel and the United States to evaluate the safety and efficacy of its C-Scan system. The company is advancing its regulatory filings with health authorities, including the U.S. Food and Drug Administration, and is preparing for potential commercialization in key markets. Led by CEO Douglas D. Eberhardt and supported by a management team with deep experience in medical devices and imaging technology, Check-Cap continues to engage in strategic collaborations and research partnerships to expand its product pipeline and geographic reach.AI Generated. May Contain Errors. Read More Check-Cap Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreCHEK MarketRank™: Check-Cap scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Check-Cap. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCheck-Cap has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.45% of the float of Check-Cap has been sold short.Short Interest Ratio / Days to CoverCheck-Cap has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Check-Cap has recently decreased by 0.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCheck-Cap does not currently pay a dividend.Dividend GrowthCheck-Cap does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.45% of the float of Check-Cap has been sold short.Short Interest Ratio / Days to CoverCheck-Cap has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Check-Cap has recently decreased by 0.51%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News SentimentN/A News SentimentCheck-Cap has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Check-Cap this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Check-Cap insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.48% of the stock of Check-Cap is held by insiders.Percentage Held by InstitutionsOnly 1.07% of the stock of Check-Cap is held by institutions.Read more about Check-Cap's insider trading history. Receive CHEK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter. Email Address CHEK Stock News HeadlinesCheck-Cap Ltd. (CHEK) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comCheck Cap Ltd News (CHEK) - Investing.comJuly 4, 2025 | investing.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.July 11 at 2:00 AM | Crypto 101 Media (Ad)MediPharm Labs Cautions Shareholders about Dissident Nominees' Governance Failures at Check-Cap ...May 23, 2025 | gurufocus.comApollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with ShareholdersMay 14, 2025 | prnewswire.comMediPharm Labs Files Proxy Materials, Issues Chair's Letter to ShareholdersMay 13, 2025 | prnewswire.comApollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value DestructionMay 8, 2025 | prnewswire.comCheck-Cap Ltd. Delays Annual Report FilingMay 1, 2025 | tipranks.comSee More Headlines CHEK Stock Analysis - Frequently Asked Questions How have CHEK shares performed this year? Check-Cap's stock was trading at $0.9899 on January 1st, 2025. Since then, CHEK shares have decreased by 20.7% and is now trading at $0.7850. How were Check-Cap's earnings last quarter? Check-Cap Ltd. (NASDAQ:CHEK) released its quarterly earnings data on Monday, November, 27th. The medical research company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.39. When did Check-Cap's stock split? Check-Cap shares reverse split before market open on Friday, November 25th 2022.The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Check-Cap IPO? Check-Cap (CHEK) raised $13 million in an initial public offering (IPO) on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager. How do I buy shares of Check-Cap? Shares of CHEK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Check-Cap own? Based on aggregate information from My MarketBeat watchlists, some other companies that Check-Cap investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA). Company Calendar Last Earnings11/27/2023Today7/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CHEK CIK1610590 Webwww.check-cap.com Phone972546706451Fax972-4821-1267Employees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.05 per share Price / Book0.20Miscellaneous Outstanding Shares5,850,000Free Float5,823,000Market Cap$4.68 million OptionableNot Optionable Beta0.19 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CHEK) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Check-Cap Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Check-Cap With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.